Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1966 1
1968 1
1977 1
1980 3
1981 2
1982 3
1983 2
1984 1
1985 1
1986 3
1987 4
1988 6
1989 4
1990 12
1991 16
1992 10
1993 7
1994 7
1995 11
1996 18
1997 14
1998 3
1999 8
2000 17
2001 15
2002 21
2003 19
2004 24
2005 33
2006 16
2007 11
2008 18
2009 10
2010 20
2011 13
2012 32
2013 23
2014 27
2015 11
2016 21
2017 22
2018 24
2019 32
2020 42
2021 36
2022 17
2023 29
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

639 results

Results by year

Filters applied: . Clear all
Page 1
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Oesterheld J, et al. Among authors: wada rk. J Clin Oncol. 2024 Jan 1;42(1):90-102. doi: 10.1200/JCO.22.02875. Epub 2023 Oct 26. J Clin Oncol. 2024. PMID: 37883734 Free PMC article. Clinical Trial.
Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapy.
Kodama M, Toyokawa G, Sugahara O, Sugiyama S, Haratake N, Yamada Y, Wada R, Takamori S, Shimokawa M, Takenaka T, Tagawa T, Kittaka H, Tsuruda T, Tanaka K, Komatsu Y, Nakata K, Imado Y, Yamazaki K, Okamoto I, Oda Y, Takahashi M, Izumi Y, Bamba T, Shimizu H, Yoshizumi T, Nakayama KI. Kodama M, et al. Among authors: wada r. Cell Rep. 2023 Aug 29;42(8):112899. doi: 10.1016/j.celrep.2023.112899. Epub 2023 Aug 1. Cell Rep. 2023. PMID: 37531252 Free article.
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. Eslin D, et al. Among authors: wada rk. Int J Cancer. 2023 Sep 1;153(5):1026-1034. doi: 10.1002/ijc.34569. Epub 2023 May 29. Int J Cancer. 2023. PMID: 37246577 Clinical Trial.
Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA1 antagonist for the treatment of systemic sclerosis.
Kobayashi Y, Uneuchi F, Naruse T, Matsuda D, Okumura-Kitajima L, Kajiyama H, Wada R, Yonemoto Y, Nakano K, Toki H, Kamigaso S, Yamagishi J, Tokura S, Kakinuma H, Kuroda S. Kobayashi Y, et al. Among authors: wada r. Eur J Med Chem. 2023 Nov 15;260:115749. doi: 10.1016/j.ejmech.2023.115749. Epub 2023 Aug 20. Eur J Med Chem. 2023. PMID: 37639822
639 results